William Grubbe (@wgrubbe_) header
William Grubbe (@wgrubbe_) profile picture
Joined October 2012
Photo by William Grubbe (@wgrubbe_)Photo by William Grubbe (@wgrubbe_)
William Grubbe retweeted
De novo design of allosterically controlled enzymes 🚀 New preprint from David Baker!🚀 1. The study presents a general de novo strategy to build compact enzymes whose catalytic activity is switched on or off by binding of a separately designed protein effector at a distal site, aiming to mimic natural allostery without domain fusions or large mechanical rearrangements. 2. Core idea: engineer an energy landscape with two nearby conformational states—an active state with catalytically optimal residue geometry and an inactive state with subtly distorted active-site geometry—then design an effector that selectively stabilizes one state to shift the equilibrium (activation or repression). 3. Methodological innovation: use partial RFdiffusion (add ~1–3 Å Gaussian noise then denoise) to generate alternative backbone conformations close to the starting enzyme fold, enriching for subtle but functionally disruptive active-site perturbations rather than large-scale motions. 4. Pipeline overview: start from a de novo serine hydrolase (Win1), generate inactive conformers by partial diffusion (with domain-wise perturbations to keep state energies close), design state-selective binders with RFdiffusion (30–80 aa), and perform multistate-compatible sequence design with tied ProteinMPNN across enzyme/effector and active/inactive contexts. 5. Allosteric activators: from 61 designed enzyme–effector pairs screened in E. coli lysates (4Mu-Ac substrate), two systems (Janus1, Janus2) showed effector-dependent activity increases and were validated with purified proteins; predicted state switching involved remodeling that restores catalytic geometry upon effector binding. 6. Activator kinetics and specificity: Janus1 kcat increased ~5-fold (0.0033→0.017 s⁻1) and Janus2 increased ~2.6-fold (0.00050→0.0013 s⁻1) at 1:2 enzyme:effector; cross-testing showed cognate specificity (non-cognate effectors did not enhance activity). 7. Allosteric inhibitors: designs were built on hydrolases for a bulkier substrate (4Mu-PhAc). A serine-to-cysteine substitution was found to broadly boost baseline catalytic efficiency in these designs and was used to increase dynamic range for observing inhibition. 8. Inhibitor performance: among 24 screened inhibitor pairs, Janus3 showed clear effector-dependent repression; purified-protein kinetics showed ~8-fold reduction in kcat upon effector binding (0.0024→0.0003 s⁻1) with little change in Km, consistent with modulation of catalytic geometry rather than substrate binding. 9. Structural validation and binding biophysics: a 1.7 Å crystal structure of the Janus3 enzyme–effector complex closely matched the design at the interface (Cα RMSD ~0.77 Å), confirming distal binding and conformational coupling. SPR measured strong affinities (Janus1 KD ~2.97 nM; Janus2 ~0.726 nM; Janus3 ~106 nM) and fast on-rates; regulation in spike-in experiments occurred within assay dead time (~21 s). 10. Coupling between catalysis and effector binding: for Janus2 and Janus3, substrate did not significantly affect effector affinity; Janus1 showed weaker binding at high substrate (KD shift ~3→13 nM), and experiments with a non-hydrolyzable analog suggested the effect is linked to catalytic turnover/acyl-enzyme intermediate formation rather than simple substrate occupancy. 📜Paper: biorxiv.org/content/10.64898… #ProteinDesign #Allostery #EnzymeEngineering #GenerativeAI #DiffusionModels #RFdiffusion #ProteinMPNN #SyntheticBiology #StructuralBiology #ComputationalBiology
1
41
3
192
12,140
A new Science #Immunology study describes a potent interleukin-21 mimic that can stimulate cytotoxic T cells and shows strong #antitumor activity in mouse models of cancer and in tumor explants derived from patients with #melanoma. scim.ag/3KsvCy9
2
29
101
4,223
Scientists have designed an interleukin-21 mimic with increased stability and capacity to induce more potent #antitumor activity than the native protein, which could inform improved #immunotherapies. @UWproteindesign Learn more in Science #Immunology: scim.ag/3KsvCy9
1
32
2
107
35,589
We sought to make proteins both potent and FAST. We used #proteindesign to design precise control over protein interaction lifetimes, enabling us to construct rapid-response circuits, biosensors, and switchable cytokines. Now published @Nature! Links to paper and tutorial below.
11
98
9
444
32,502
I am happy to share that we have a great opportunity for a postdoctoral scientist. Please share. hhmi.wd1.myworkdayjobs.com/e…
5
2
10
1,887
Congratulations to the new graduates of @UChicagoPME !!
Today, the University of Chicago Pritzker School of Molecular Engineering celebrated the Class of 2025—an exceptional group of innovators and researchers ready to shape the future of #science, #engineering, and #technology. From breakthroughs in quantum science, health, and sustainability to bold entrepreneurship, this graduating class has left its mark on UChicago and the world. #UChicagoPME #UChicagoPMEGrad #UChicago2025
1
3
247
William Grubbe retweeted
Fantastic work coming out of @DrJuanLMendoza lab recently! Structural and signaling dynamics of an interesting cytokine in the interferon family, IFNL4, thanks to a breakthrough that allowed the team to express the protein in high quantity and purity. nature.com/articles/s41467-0…
1
8
693
#UChicagoPME researchers in the @DrJuanLMendoza Group have developed a method to produce an immune protein to facilitate future studies on why it makes immune responses worse. 📰pme.uchicago.edu/news/protei…
1
4
18
1,213
🚨 New Episode of In Translation 🚨 Great sitting down with @JefBoeke and @theicechol to talk synthetic genomics! Hope you enjoy!
1
4
332
William Grubbe retweeted
We are all born with a genetic lottery. Millions of T cell receptors are what we have with a hope to defend all cancer and viruses. What if that's not enough? Hope our work can give an interesting answer to you. biorxiv.org/content/10.1101/…
9
43
3
232
27,714
Great story and great technology from @adam_broerman, @UWproteindesign, and others. Excited to apply this to the next generation of cytokine therapeutics! #proteindesign
Excited to announce our new #proteindesign strategy for allosterically controlling the kinetics of protein-protein interactions! Read on for cool applications in cytokine signaling, biosensing, and protein circuits. biorxiv.org/content/10.1101/…
1
1
9
720
Great talk @DrJuanLMendoza! Having a great time in Seoul and thank you to @CytokineSociety for the generous Travel Award allowing me to present my work here!
I was happy to have presented the work of Will Grubbe, today, highlighting his significant contribution to IFN biology at Cytokines 2024. @wgrubbe_ @CytokineSociety PS. photo before session 😆
1
1
9
952
William Grubbe retweeted
BREAKING NEWS The Royal Swedish Academy of Sciences has decided to award the 2024 #NobelPrize in Chemistry with one half to David Baker “for computational protein design” and the other half jointly to Demis Hassabis and John M. Jumper “for protein structure prediction.”
504
8,278
3,233
18,998
9,117,944
Call for Abstract Extended Deadline for Cytokines 2024 / KAI 2024 - May 30, 2024 (23:59 KST)! For ICIS Student/Postdoc members the travel award application is also extended until May 30th #cytokines2024 Please retweet and plan to share your cytokine science at the joint meeting.
7
1
9
4,877